Bruker (BRKR) Reports In-Line Q4 EPS, Offers FY Guidance

Bruker (NASDAQ: BRKR) reported Q4 EPS of $0.54, in-line with the analyst estimate of $0.54. Revenue for the quarter came in at $553.6 million versus the consensus estimate of $544.6 million.

GUIDANCE:

Bruker sees FY2019 EPS of $1.54-$1.58, versus the consensus of $1.55.

For FY 2019, the Company expects 6% to 7% year-over-year revenue growth, including the following estimates:

• organic revenue growth of 4% to 5%,
• revenue growth from acquisitions of 4%, with constant-currency revenue growth of 8% to 9%, and
• a negative foreign currency translation effect on revenue of 2%.

For earnings history and earnings-related data on Bruker (BRKR) click here.

You May Also Be Interested In

• Delta Air Lines (DAL) Tops Q2 EPS by 3c, Beats on Revenue; Offers Guidance
• Ionis Pharmaceuticals (IONS) reaffirms guidance
• Helen of Troy (HELE) Tops Q1 EPS by 22c, Beats on Revenue; Offers FY Guidance